Meiji Holdings Co., Ltd.
Q1 FY2027 Financial Summary (Consolidated)
For Q1 of the fiscal year ending March 2027, consolidated net sales were 289,401 million yen (up 5.8% YoY), operating income was 22,673 million yen (up 27.7% YoY), ordinary income was 24,790 million yen (up 37.8% YoY), and net income attributable to owners of the parent was 15,271 million yen (up 51.3% YoY). Full-year guidance unchanged. Segments: both foods and pharmaceuticals remained solid, with pharmaceuticals benefiting from new product promotions and overseas revenue contributions. Preparation of the supplementary materials for the earnings release and a briefing session are planned.
Key Figures
- Sales: 289,401百万円
- Operating income: 22,673百万円
- Net income attributable to owners of the parent: 15,271百万円
AI要約
Business Performance Overview
For the Q1 of the fiscal year ending March 2027, consolidated net sales reached 289,401 million yen, up 5.8% YoY, operating income was 22,673 million yen, up 27.7% YoY, ordinary income was 24,790 million yen, up 37.8% YoY, and net income attributable to owners of the parent was 15,271 million yen, up 51.3% YoY, marking substantial profit growth. Segments show solid performance in both foods and pharmaceuticals. Plans exist to prepare the earnings release supplementary materials and hold an analyst briefing.
Outlook and Points of Attention
Full-year guidance remains unchanged from the time of the forecast. Remaining risks include currency and raw material cost movements and geopolitical factors. In the Pharmaceuticals segment, new product adoption and growth in plasma-derived products contribute to profits. In the Foods segment, higher raw material costs are being absorbed, and cost reduction and productivity improvements continue to take effect. Refer to the earnings briefing materials and appendices.
Meiji Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
